Compounds > 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide

Page last updated: 2024-11-13

5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide: metabolite of dacarbazine; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	135518056
CHEBI ID	143355
SCHEMBL ID	826407
MeSH ID	M0088564

Synonyms (12)

Synonym
hmic
imidazole-4-carboxamide, 5-(3-(hydroxymethyl)-3-methyl-1-triazeno)-
5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide
1h-imidazole-4-carboxamide, 5-(3-(hydroxymethyl)-3-methyl-1-triazenyl)-
5-(3-(hydroxymethyl)-3-methyl-1-triazeno)imidazole-4-carboxamide
CHEBI:143355
AKOS006279310
unii-ao5r5iqw25
75513-70-1
ao5r5iqw25 ,
hmmtic
SCHEMBL826407

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

Class	Description
heteroarene	A heterocyclic compound formally derived from an arene by replacement of one or more methine (-C=) and/or vinylene (-CH=CH-) groups by trivalent or divalent heteroatoms, respectively, in such a way as to maintain the continuous pi-electron system characteristic of aromatic systems and a number of out-of-plane pi-electrons corresponding to the Hueckel rule (4n+2).
aromatic amide	An amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (28.57)	18.7374
1990's	1 (14.29)	18.2507
2000's	1 (14.29)	29.6817
2010's	2 (28.57)	24.3611
2020's	1 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (14.29%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
temozolomide [no description available]	4.07	3	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
aminoimidazole carboxamide Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.	2.39	2	0	aminoimidazole; monocarboxylic acid amide	mouse metabolite
5-(3-methyl-1-triazeno)imidazole-4-carboxamide 5-(3-methyl-1-triazeno)imidazole-4-carboxamide: structure; RN given refers to parent cpd. MTIC : A monocarboxylic acid amide that is dacarbazine in which one of the methyl groups is replaced by a hydrogen. It is the active metabolite of dacarbazine, and is also produced by spontaneous hydrolysis of temozolomide in the body.	9.47	5	0	imidazoles; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent
5-(3,3-dimethyl-1-triazeno)-1-methylimidazole-4-carboxamide 5-(3,3-dimethyl-1-triazeno)-1-methylimidazole-4-carboxamide: metabolite of dacarbazine	1.95	1	0
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	9.89	8	0	dacarbazine

Condition	Indicated	Relationship Strength	Studies	Trials
Complications, Neoplastic Pregnancy [description not available]	0	2.17	1	0
Granuloma, Hodgkin [description not available]	0	2.17	1	0
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	0	2.17	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.17	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.05	1	0
Germinoblastoma [description not available]	0	4.84	4	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	0	4.84	4	0